Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: NeuroControl

This article was originally published in The Gray Sheet

Executive Summary

NeuroControl: Receives $7.6 mil. in additional equity funding from existing and new investors. New investors include: McDonald & Company; Morgenthaler Ventures; Robertson Stephens & Company; and Wessels, Arnold & Henderson. Primus Venture Partners, the Cleveland Clinic Foundation and Invacare increased their stakes in the Cleveland-based firm. A portion of the proceeds will go toward marketing of NeuroControl's Freehand neuroprosthesis following anticipated FDA approval later this year ("The Gray Sheet" Sept. 30, 1996, p. 11). Funds also will go toward consolidating European marketing and completing U.S. clinical trials of the firm's Vocare bladder/bowel control implant ("The Gray Sheet" May 13, 1996, I&W-5). The firm also plans to "build staff, including field representatives worldwide, and accelerate new product development"...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT007624

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel